A New York overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
In 2024, an estimated 29.5% of New York adults had obesity, per the CDC's Behavioral Risk Factor Surveillance System — the state's fourth straight year in a narrow 28%-to-30% band (29.1% in 2021, 30.1% in 2022, 28.0% in 2023) 12. Close to three in ten New York adults meet the clinical threshold for obesity, and that share hasn't meaningfully shifted in half a decade.
New York's population grew in 2024 for the first time since the pandemic-era declines — up roughly 163,500 residents to 19,867,248 (Census Vintage 2024) 3.
New York Medicaid does not cover GLP-1 medications for obesity on its own. NYRx, the Medicaid Pharmacy Program run jointly by NYS DOH and Prime Therapeutics, sets coverage through a Preferred Drug List — the version in force now is dated "Revised: July 16, 2026" 6. It lists exactly two anti-obesity GLP-1 products, each gated behind a comorbidity most people with obesity don't have. Semaglutide (Wegovy) requires a confirmed cardiovascular-disease diagnosis plus a BMI of 40 kg/m² or higher and documented lifestyle-modification participation, capped at two treatment attempts per lifetime. Tirzepatide (Zepbound) requires the same BMI threshold and lifestyle criteria but swaps in a confirmed obstructive-sleep-apnea diagnosis, with the same two-lifetime-attempt cap 6.
Both are recent additions — comparing the state's own archived PDL snapshots shows the Wegovy criterion appeared between the Nov. 6, 2025 and Nov. 20, 2025 revisions 78, and the Zepbound criterion between the June 4, 2026 and July 16, 2026 revisions 96. Neither "obesity" nor Saxenda (liraglutide's weight-loss brand) appears anywhere in the PDL's 86 pages; liraglutide is listed only as a diabetes drug 6.
There is no pathway for a plain obesity diagnosis (ICD-10 E66.x) without a qualifying comorbidity, and because NYRx's own materials describe "consistent management strategies across the NYRx and managed care pharmacy benefits," this restriction appears to reach Medicaid Managed Care claims too, not just fee-for-service 10. We could not find a New York State Department of Health statement that explicitly confirms the obesity-alone exclusion in plain language — health.ny.gov blocked automated access during this research pass — so this reading is drawn directly from the PDL document itself, not from a DOH policy announcement.
Astra's price does not change inside New York, because it isn't a New York price — it's the same $68/month for semaglutide and $118/month for tirzepatide (both 12-month plans, billed as $816 and $1,416 annually) everywhere Astra operates.
New York's 2024 median household income was $85,820 (ACS 1-year estimate) 4 — above the national median — and the state's uninsured rate is comparatively low, around 4.9% (roughly 974,000 people) in 2024 5. That means most New Yorkers priced out of GLP-1 coverage aren't uninsured outright — they're insured people whose plan excludes weight-loss drugs, or Medicaid enrollees who don't clear the comorbidity bar above.
New York's obesity-medicine and endocrinology capacity is concentrated in its academic medical centers — largely downstate and in a handful of upstate hubs — leaving long stretches of the state without a nearby specialist taking new weight-management patients. [TODO: pull current HRSA HPSA designations for New York before publish — not gathered in this research pass.] Telehealth removes the geography problem: a licensed clinician can manage a GLP-1 regimen for a patient anywhere in the state the same way as one a few blocks from a specialist's office, without the drive.
New York's specific telehealth practice rules — physician licensure requirements, any audio-only allowances, and current parity-law details — are administered through the NYS Education Department's Office of the Professions (op.nysed.gov) and the NYS Department of Health. [TODO: confirm current NY telehealth/licensure rules against op.nysed.gov and health.ny.gov before publish; health.ny.gov returned HTTP 403 to automated fetches throughout this research pass.]
Astra is licensed and available across all 50 states, New York included — a resident anywhere in the state, from Buffalo to Montauk, can start care today with no state-specific eligibility restriction beyond the standard medical intake.
Astra treats patients in New York through state-licensed physicians.
This hub connects to Astra's New York city pages, each checked against locally published clinic prices:
No — Astra's price doesn't change by state or city. Semaglutide is $68 a month and tirzepatide is $118 a month, both on 12-month plans ($816 and $1,416 billed annually), whether you're in Buffalo, Manhattan, or anywhere else Astra operates. If you want to see how that compares to what local clinics charge, check the Buffalo, Rochester, or Syracuse pages, where we track locally published prices directly.
Only in a narrow set of cases. Per the state's NYRx Preferred Drug List (Revised July 16, 2026), Wegovy is covered only for patients with a confirmed cardiovascular disease diagnosis and a BMI of 40 or higher, and Zepbound only for patients with confirmed obstructive sleep apnea and the same BMI threshold — both capped at two treatment attempts per lifetime. There is no listed coverage pathway for obesity alone.
Based on the current NYRx PDL, no — the document lists no coverage pathway for obesity by itself (ICD-10 E66.x) without a qualifying cardiovascular-disease or obstructive-sleep-apnea diagnosis. This criterion is recent (added within the past year) and could change again, so it's worth confirming directly with your plan before assuming either way.
Yes. Astra is licensed to treat patients throughout New York State, not just the downstate metro area — the same telehealth intake, prescribing, and pricing apply whether you're in Buffalo, Rochester, Syracuse, or anywhere else in the state.
A licensed clinician reviews your health history and current medications through a telehealth visit, then prescribes and manages your GLP-1 regimen remotely — no in-person specialist visit required. [TODO: confirm current NY-specific telehealth practice and licensure rules — not independently verified this research pass.]
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.